This partnership leverages LOTTE BIOLOGICS' extensive proficiency in antibody manufacturing and NJ Bio's specialized skills in ADC process development, as well as linker-payload synthesis. Clients will benefit from access to end-to-end solutions provided by the collaborative efforts of these industry leaders, all facilitated by our state-of-the-art bio plant in Syracuse, New York.

The services offered through this partnership are tailor-made for phase 3 clinical trials and the commercial production of Antibody-Drug Conjugates, ensuring a seamless transition from clinical development to commercialization. Our bio plant in Syracuse, New York, serves as the epicenter for these operations, equipped with cutting-edge technologies and staffed by a team of seasoned professionals dedicated to ensuring the success of our clients' endeavors.

"Our strategic partnership with NJ Bio marks a significant milestone for LOTTE BIOLOGICS as we continue to enhance our ADC capabilities," said Spokesperson's  at LOTTE BIOLOGICS. "By combining our strengths, we aim to provide unparalleled services to our clients, positioning Syracuse as the premier ADC contract manufacturing service center within North America."

The collaboration between LOTTE BIOLOGICS and NJ Bio is strategically focused on transforming the Syracuse site into a hub for ADC innovation, setting new industry standards and exceeding client expectations. This partnership reflects LOTTE BIOLOGICS' commitment to advancing the field through strategic collaborations and open innovations.